Is there a there there?
You have an idea worth defending. Before your organization commits capital it cannot get back, you need a structured external verdict — not another internal opinion, and not a framework workshop.
The Venture Architecture Diagnostic™ is a 14-work-day sprint that produces one of four evidence-backed verdicts on your corporate venture idea: GO, PIVOT, WRONG COMPANY, or NO-GO. Every verdict comes with a forward path. Every engagement is led personally by Thomas Calvert — 20+ years of Intel incubation experience, $15M+ raised for internal startups, $200M+ in strategic value delivered. The VAD runs on a structured AI toolkit — six purpose-built tools deployed across every analytical stream. The AI accelerates the analysis. Thomas provides the judgment that determines what the evidence means.
You're not losing sleep over the idea. You're losing sleep over what happens if you're wrong.
Most corporate ventures don't fail because the idea was bad. They fail because the organization committed Stage 3 resources to a Stage 1 hypothesis — and nobody had the structural framework, or the political standing, to surface that problem before the money was spent.
Less than 10% of a venture's total lifetime capital is deployed before the scale decision. That early window sets the direction for everything that follows. And yet most organizations spend it without a structured diagnostic: workshops, yes. Ideation sessions, yes. A rigorous external assessment of whether this host organization can actually execute what the venture requires — almost never.
Boards are not demanding diagnostics because ventures got riskier. They are demanding them because activity masquerading as governance finally got expensive enough to notice. The pendulum is swinging from innovation activity to innovation governance — and the organizations that catch that shift before their peers will protect capital the others will spend finding out the expensive way.
You know the failure data. What you need is someone who has been in the chair you are sitting in, who has raised internal capital and defended ideas to skeptical CFOs — and who can tell you honestly whether this one has a there there. That is the engagement. Fourteen work days. One structured verdict. A forward path regardless of what the evidence shows.
New corporate product launches fail
(McKinsey)
Organizations run innovation with no framework
(Accenture)
RPP scores below 2 predict NO-GO or WRONG COMPANY
(THC Pattern Library, N=128)
The 1/10/100 Principle
Generating an idea costs a dollar. Developing it into a product costs ten. Commercializing it at scale costs a hundred — and if you are creating a new category, closer to two hundred. Most ventures do not fail at the idea stage. They fail at stage three, after the organization has already spent a hundred dollars proving an idea that a structured sprint could have flagged at the one-dollar stage.
In most corporate venturing portfolios, less than 10% of total lifetime venture capital is deployed before the decision to scale. That 10% determines whether the remaining 90% is well-placed. The Venture Architecture Diagnostic™ is a low-five-figure gate inserted at Stage 1 — before a potential $3–4M Stage 3 commitment locks in. That is the math. Everything else is downstream of it.
The VAD is the structured gate between the $1 idea and the $10 product investment. It exists to answer the most expensive question in corporate innovation before the answer gets expensive.
Core assumptions hold. Structural fit confirmed. Proceed to Stage 2 with confidence. Forward path: named experiments for the next 30–60 days.
Promising signal, wrong configuration. Specific pivot conditions named. Forward path: exact change required defined before you leave Day 14.
The idea has merit — but not in this host. Forward path: licensing, partnership, spin-out, or structured handoff identified.
The hypothesis does not hold. Capital preserved before commitment deepens. Forward path: protection of the venture lead's credibility and political capital.
Every verdict — including NO-GO — arrives with a named forward path. The engagement does not end at the verdict. THC stays in the room.
GO
The evidence holds.
The RPP scoring confirms structural fit: the venture hypothesis, the host organization's resources and incentive structures, and the target market timing all align. Move forward with confidence.
PIVOT
Real signal. Wrong configuration.
The data shows genuine market opportunity, but the current organizational framing won't reach it. The sprint identifies the specific structural changes required for a viable path forward.
WRONG COMPANY
The idea has merit. This organization doesn't.
The venture hypothesis is sound. The problem is the host: the capabilities, incentive structures, or strategic priorities here are structurally misaligned. Partnership or spin-out is the path.
NO-GO
Capital preserved.
The hypothesis does not hold. The evidence — customer signals, market dynamics, competitive structure, or unit economics — does not support advancing this venture in any form.
How the Analysis Gets Done
A standard VAD engagement runs 6–8 hours of direct Thomas attention per day across 14 work days. Approximately 60% of the analytical work is AI-assisted — live market research, assumption extraction, adversarial probing, financial modeling inputs, and pattern matching across 128 catalogued venture cases.
Thomas provides the remaining 40%: live client engagement, structural scoring judgment, contextual pattern recognition, and final narrative synthesis.
The AI does not produce verdicts. It handles the analytical volume that would otherwise require a team. Thomas is the quality gate on everything it surfaces — and the sole author of the verdict.
The Seven Deliverables
Every engagement produces the same seven structured outputs — regardless of verdict.
Sprint Master Report
20–30 pages. Full diagnostic narrative, evidence base, analytical trail, and verdict rationale. Includes the Known Limitations disclosure — named in the report, not hidden in footnotes. The document the venture lead takes into the CFO conversation.
See sample report →RPP Strategic Fit Assessment
Resources, Processes, Priorities alignment scored against an 8-question rubric. Determines whether your organization can host this venture at all — and if so, under what structural conditions. The most predictive single diagnostic in the methodology. At N=128, an RPP score at or below 2 predicts NO-GO or WRONG COMPANY in 96% of cases.
See sample report →Market Intelligence Brief
TAM, SAM, and SOM analysis built on sourced data and adjusted downward from the optimistic top-down estimates internal teams typically present. The number your CFO can defend, not the number that makes the slide look good. Competitive landscape and ecosystem map included.
See sample report →Unit Economics & Financial Model
CAC, LTV, payback period, and reverse P&L across Optimistic, Base Case, and Bear Case scenarios. All three built on bias-calibrated inputs from the Black Box Bias Audit. The model that tells you whether the economics work before you spend $3M finding out they do not.
See sample report →Assumption & Risk Register
Full inventory of every untested assumption in your hypothesis — explicit and implicit — ranked by importance and certainty. Typical output: 30–60 assumptions, including ones the internal team has never stated aloud. The top Critical Unknowns drive the Validation Experiment Playbook.
See sample report →Black Box Bias Audit
A proprietary five-technique adversarial protocol that occupies the space no internal team can fill: the well-informed adversary with no political stake in the outcome. Five techniques: (1) Assumption Extraction — minimum 30–60 assumptions surfaced, 40%+ implicit; (2) Adversarial Probing — every challenge specific, evidence-grounded, and falsifiable; (3) Historical Pattern Matching — at least 3 Pattern Library analogs assessed; (4) Two-Stage Pre-Mortem — failure scenarios generated independently, then walked through with the sponsor on Day 12; (5) Optimism Quantification — base-rate-adjusted model produced alongside the sponsor team's model. The audit runs on structured AI protocols — adversarial prompting at a scale and speed no analyst team replicates at this price point. The differentiator is the practitioner who designed the protocol and interprets what it surfaces. The audit is the proof of it.
See sample report →Validation Experiment Playbook
3–5 prioritized experiments for 30–60-day post-sprint validation. A named agenda for Stage 2 — not a pile of options — with pre-agreed verdict revision triggers built in. If the experiments produce evidence that contradicts the verdict, the playbook names the conditions that would trigger a PIVOT or re-sprint. The engagement does not end at the verdict.
See sample report →Engagement Options
The fee fits CFO discretionary authority. The methodology does not cut corners to get there.
Quick Scan
3 work daysThomas-led diagnostic memo. Rapid hypothesis screen. A single honest senior-level answer to the most pressing question your venture is sitting on right now.
Book a Discovery CallBase Sprint (VAD)
14 work daysAll 7 deliverables. All 8 analytical streams. One structured verdict. The flagship engagement.
Book a Discovery CallSprint + Exec Presentation
14 work days + prepFull sprint plus a structured internal stakeholder readout deck built for your board, executive team, or investment committee. Most verdicts die in translation. This tier keeps that from happening.
Book a Discovery CallSprint + 60-Day Validation
14 work days + 60 daysFull sprint plus 4 hours/month of direct Thomas engagement through the critical Stage 2 validation window. We do not build the MVP. We help you know whether what you are building is the right thing to build — before the Stage 2 capital commits at scale.
Book a Discovery CallWho is behind this
I spent twenty-three years at Intel building businesses from blank whiteboards. I raised internal capital for ventures in logistics, pharma analytics, fintech, and AI. I managed ten equity investments at Intel Capital totaling $55M — including early positions in iZettle, CashStar, and SecureKey that generated $200M+ in strategic value.
Some of it I got right. A fintech ecosystem play I restructured as a financial services partnership — rather than forcing it through Intel's semiconductor-focused operating model — generated $10M+ in annual revenue in its first commercialization year. Some of it I got wrong. A logistics analytics venture I defended for six months before an honest structural read in week two would have surfaced the misfit. The methodology THC uses today exists because that mistake was avoidable and expensive.
The Venture Architecture Diagnostic™ is the structured process I wish I'd had in the chair. Every sprint is led personally by Thomas — no junior analysts, no delegated delivery — from kickoff through Day 14 verdict delivery and beyond.
The VAD is AI-augmented by design. Not because AI produces verdicts — it does not — but because it handles the analytical volume that would otherwise require a team of junior analysts, and does it faster and more consistently than a team could. What remains — the structural judgment calls, the client reads, the final synthesis — is Thomas, personally, in every engagement.
Common Questions
The Venture Architecture Diagnostic (VAD) is a 14-work-day corporate venture diagnostic, led personally by Thomas Calvert, that produces one of four evidence-backed verdicts on a corporate venture idea before the organization commits Stage 2 capital. It is a structured external verdict — not an internal opinion, and not a framework workshop.
GO — core assumptions hold and structural fit is confirmed; proceed to Stage 2. PIVOT — promising signal but the wrong configuration; specific pivot conditions are named. WRONG COMPANY — the idea has merit but not in this host organization; a licensing, partnership, or spin-out path is identified. NO-GO — the hypothesis does not hold and capital is preserved. Every verdict arrives with a named forward path.
A Quick Scan is $2,500 over 3 business days. The Base Sprint is $15,000–$20,000. Sprint plus Executive Presentation is $20,000–$25,000. Sprint plus 60-Day Validation is $35,000–$45,000. Two further tiers support specific situations: a Re-Sprint following a PIVOT reframe is $10,000–$15,000 over 7 work days, and Stage 2 Validation Advisory is $5,000 per month for post-GO execution support.
Mid-market companies — roughly $200M to $2B in annual revenue — that operate an active corporate venture or incubation function and are weighing whether to commit Stage 2 capital to a specific idea. It is most useful at the decision point before significant build spend, when a wrong answer is still inexpensive to discover.
The most expensive question in corporate innovation deserves a structured answer.
Book a 30-minute discovery call. No pitch. No framework presentation. A direct conversation about whether the VAD is the right engagement for where your venture sits right now.